Woman of the Week: Genentech’s Veronica Sandoval

How the Genentech diversity exec is using ‘three Ms’ to reduce health disparities and improve access for under-supported communities.

By Taren Grom • May 17, 2023

From farm to pharma: How cows could play a role in the next flu breakthrough

SAb Biotherapeutics is working on a novel product that uses cow antibodies genetically engineered into human antibodies to prevent and treat infectious diseases.

By Alexandra Pecci • May 16, 2023

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

How pharma’s rocky real estate market has changed — for better and worse

Whether you’re looking to build a new site or expand lab space, here are the biggest trends impacting life sciences real estate.

By Karissa Waddick • May 11, 2023

Woman of the Week: Reneo Pharmaceuticals’ Ashley Hall

After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.

By Taren Grom • May 10, 2023

This ‘hot-blooded’ CEO is aiming to transform the way burn victims heal

Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.

By Alexandra Pecci • May 9, 2023

Led by the Pfizer-Seagen deal, ADCs are starting to ‘take center stage’

Antibody-drug conjugates got a major boost with the megamerger of Pfizer and Seagen, and experts believe they will continue to be an important catalyst in biopharma.

By Michael Gibney • May 9, 2023

3 key FDA approval trends this year

Although approvals are off to a slow start in oncology, the agency has been living in the fast lane for neurological disorders and more.

By Kelly Bilodeau • May 8, 2023

How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

By Taren Grom • May 5, 2023

Navigating workforce challenges amid a turbulent biopharma market

A number of biopharma companies slashed their workforces this year and as market anxieties persist, more challenges could be looming.

By Karissa Waddick • May 4, 2023

A biopharma CEO opens up about executive salaries — and why he wants to change the status quo

With leaders at the biggest biopharma companies bringing in millions, the CEO of Corvus Pharmaceuticals opted for a pay cut to pour more funds into science.

By Michael Gibney • May 4, 2023

Attracting up-and-coming talent in biotech

The CEO of a Bay-area startup shares his strategies for growing a team from the ground up.

By Meagan Parrish • May 3, 2023

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023

Taking your biotech global? Here’s how you can navigate cultural norms

What’s so different about doing pharma business in the U.K. versus Japan? One of Moderna’s top brass shares her tips for navigating choppy cultural waters.

By Alexandra Pecci • May 2, 2023

From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of "knock your socks off" antibodies.

By Michael Gibney • May 2, 2023

A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient

The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.

By Taren Grom • May 1, 2023

Emalex aims at a first-in-class breakthrough for Tourette syndrome

With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

By Kelly Bilodeau • May 1, 2023

Pharma’s immunology field is full of blockbusters, and it’s just getting started

From the "father" of the IL-23 pathway at Janssen to a big acquisition by Merck, the ultra-competitive immunology space is still growing with the pace of innovation.

By Michael Gibney • April 27, 2023

How biopharma dealmaking kicked back into action

Events over the last year, including Pfizer’s Seagen buy and AstraZeneca’s CinCor deal, have foreshadowed the comeback of biopharma M&A.

By Michael Gibney • April 27, 2023

Scientists could finally be closing in on a ‘pill’ for men

Drug developers have tried — and failed — to create a male contraceptive for decades. Now, one group of scientists might be on the verge of success.

By Kelly Bilodeau • April 26, 2023

Roy Vagelos is retiring and leaving a legacy of leadership lessons

The longtime pharma leader is stepping down from his role as chair of Regeneron’s board in June after decades in drug development. 

By Karissa Waddick • April 25, 2023

20 years on, the next stage of the human genome revolution is brewing

Two decades after the Human Genome Project, scientists are on the brink of uncovering its full potential for drug development.

By Karissa Waddick • April 24, 2023

Cure Ventures has $350M to pour deep into biotech ‘company building’

The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.

By Michael Gibney • April 20, 2023

Conditions for worker burnout in biotech are ripe. Here’s how to beat it

One of the country’s leading burnout experts explains how companies can help keep high stress from becoming a high desire to leave the job.

By Meagan Parrish • April 19, 2023

Woman of the Week: Brii Biosciences’ Ellee de Groot

A chemical engineer by training, Brii’s chief technology officer is applying her experience to solve research problems from the clinic to commercial development.

By Taren Grom • April 19, 2023

Depression has long been treated chronically — Sage wants to change that

Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

By Michael Gibney • April 18, 2023